It’s not often that you see a standing ovation at a medical conference. But over the weekend, a ballroom full of cancer specialists got to their feet to applaud a slide showing that Revolution Medicine’s daraxonrasib had doubled the survival time of patients with pancreatic cancer.
Intelligence Bloomberg Jun 2, 2026